Abstract. Sepsis, an acute systemic inflammatory response syndrome caused by severe infection, is one of the leading causes of in-hospital mortality. Our recent work provides evidence that mortality rate in sepsis patients can be significantly reduced by Hemoadsorption (HA) therapy with duration determined by a data-driven approach. The therapy optimization process requires predicting high-mobility group protein B-1 concentration 24 hours in the future. However, measuring sepsis biomarkers is very costly, and also blood volume is limited such that the number of available temporal observations for training a regression model is small. The challenge addressed in this study is how to balance the trade-off of prediction accuracy versus the limited number of temporal observations by selecting a sampling protocol (biomarker selection and frequency of measurements) appropriately for the prediction model and measurement noise level. In particular, to predict HMGB1 concentration 24 hours ahead when limiting the number of blood drawings before therapy to three, we found that the accuracy of observing HMGB1 and three other cytokines (Lsel, TNF-alpha, and IL10) was comparable to observing eight cytokines that are commonly used sepsis biomarkers. We found that blood drawings 1-hour apart are preferred when measurements are noise free, but in presence of noise, blood drawings 3 hours apart are preferred. Comparing to the data-driven approaches, the sampling protocol obtained by using domain knowledge has a similar accuracy with the same cost, but half of the number of blood drawings.
Introduction and Motivation
Sepsis is a serious condition resulting from uncontrolled systematic inflammatory response to some pathogen infections. This condition is characterized by fast progression, severe symptoms and high mortality rate. In fact this is the number one cause of in hospital death in the USA [1] . Despite the high importance of the problem and substantial amount of researchers effort, not much progress has been achieved in resolving it. The vast heterogeneity of clinical manifestations makes identification of sepsis severity challenging. Another difficulty lies in rapid progression of the condition, where a patient goes from mild symptoms of infection to life threatening systematic inflammation condition in just several hours. Treatment consists of administering cocktails of various antibiotics in order to cover the spectrum of possible pathogens (usually bacteria) as much as possible. Even this aggressive treatment often is not enough since mortally in severe sepsis is as high as 30% and up to 70% when septic shock occurs [2] .
Two main challenges arise in the problem of reducing the lethality of the sepsis. First it is very important to devise accurate diagnostic techniques that are also able to classify condition as early as possible. After correct diagnosis, it may be even more important that therapy is applied timely and appropriately. Since, in order to be effective, sepsis therapy should be aggressive, treating a person that is healthy is almost as undesirable as not treating an ill patient. The problems of early and accurate diagnostics have been addressed in a number of articles, such as [4], [5] and [8] . Recently, a form of blood purification called Hemoadsorption (HA) was proposed as a complement to antibiotic therapy. It was shown that HA is beneficial when used in animal models of sepsis [6] . It is based on removing certain cytokines from the blood, which are involved in mechanisms of systemic inflammation. Systemic inflammation takes place when these biomarkers enter a positive feedback loop with immune cells resulting in uncontrollable increase in inflammation. This process is known as a cytokine storm and it plays major role in number of conditions including sepsis. By cytokine reduction, HA therapy attempts to regain control over the inflammation process and return it to normal mode.
Given their roll in development of sepsis, observing cytokines over time is beneficial in both diagnostic and therapeutic purposes. Recently, they were used in the task of early classification of septic patients [8] . It is shown that applying HA therapy can be guided according to the predicted future values of cytokines in the Model Predictive Control framework [3] . On the other hand, there are also some constraints on cytokines use in the task of predicting sepsis progression. Constraints are mainly posed by limits on various resources. With current technologies fairly large volume of blood is needed to measure a particular (single) cytokine. However, there are at least 150 different cytokines, and many of them are involved in the inflammation process. Instead of measuring all cytokines, in clinical applications just a few of the most informative should be identified. Even when just a few cytokines are measured, measurement needs to be done on a number of different chronological occasions in order to catch the temporal dynamics of their change, which also increases demands on blood that needs to be drawn. In reality the amount of blood that can be drawn from a subject is a limiting factor in temporal observations of cytokines. The total amount of blood drawn over some period of time is limited by cost, data extraction time and even medical protocols. An additional constraint in small animals experiments (e.g mice and rats) is that drawing too much blood can interfere with the state of the subject since volume of the subject's bodily fluids is small.
